Effect of pulsatile administration of levodopa on dyskinesia induction in drug‐naïve MPTP‐treated common marmosets: Effect of dose, frequency of administration, and brain exposure

Levodopa (L‐dopa) consistently primes basal ganglia for the appearance of dyskinesia in parkinsonian patients and 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine hydrochloride (MPTP) ‐treated primates. This finding may reflect its relatively short duration of effects resulting in pulsatile stimulation of postsynaptic dopamine receptors in the striatum. We have compared the relationship between L‐dopa dose and frequency of administration on dyskinesia initiation in drug‐naïve, MPTP‐treated common marmosets. We have also studied the effect of increased brain exposure to pulsatile administration by combining a low‐dose of L‐dopa with the peripheral catechol‐O‐methyltransferase inhibitor (COMT‐I), entacapone. Pulsatile administration of a low (dose range, 5.0–7.5 mg/kg p.o.) or a high (12.5 mg/kg) dose of L‐dopa plus carbidopa b.i.d. produced a dose‐related reversal of motor deficits. Repeated administration of low and high doses of L‐dopa for 26 days to drug‐naïve, MPTP‐treated animals also caused a dose‐related induction of peak‐dose dyskinesia. Repeated administration of high‐dose L‐dopa b.i.d. compared to once daily caused a frequency‐related improvement of motor symptoms, resulting in a more rapid and initially more intense appearance of peak‐dose dyskinesia. Administration of low‐dose L‐dopa b.i.d. for 26 days in combination with entacapone enhanced the increase in locomotor activity and reversal of disability produced by L‐dopa alone, but with no obvious change in duration of L‐dopa's effect. However, combining entacapone with L‐dopa resulted in the more rapid appearance of dyskinesia, which was initially more severe than occurred with L‐dopa alone. Importantly, increasing pulsatile exposure of brain to L‐dopa by preventing its peripheral breakdown also increases dyskinesia induction. © 2003 Movement Disorder Society

[1]  M. Kurosumi,et al.  A Pure Antiestrogen, ICI 182,780, Stimulates the Growth of Tamoxifen-Resistant KPL-1 Human Breast Cancer Cells in vivo but not in vitro , 1998, Oncology.

[2]  S Fahn,et al.  The spectrum of levodopa-induced dyskinesias. , 2000, Annals of neurology.

[3]  Rinne Uk,et al.  A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. , 1996 .

[4]  J. Langston,et al.  Levodopa induces dyskinesias in normal squirrel monkeys , 2001, Annals of neurology.

[5]  G. Block,et al.  Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. , 1997, European neurology.

[6]  T. Di Paolo,et al.  Levodopa-Induced Dyskinesia: Facts and Fancy. What Does the MPTP Monkey Model Tell Us? , 1992, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[7]  K. Lange,et al.  Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to normal common marmosets , 2005, Psychopharmacology.

[8]  S. Iversen,et al.  Characterisation of dyskinesias induced byl-dopa in MPTP-treated squirrel monkeys , 2005, Psychopharmacology.

[9]  J. Cedarbaum,et al.  Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys: implications for the treatment of Parkinson's disease. , 1991, Clinical neuropharmacology.

[10]  M. Mark,et al.  Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease , 1998, Movement disorders : official journal of the Movement Disorder Society.

[11]  J. Bennett,et al.  Dose-related effects of continuous levodopa infusion in rats with unilateral lesions of the substantia nigra , 1996, Brain Research.

[12]  J M Cedarbaum,et al.  L‐Deprenyl (Selegiline) Added to Sinemet CR in the Management of Parkinson's Disease Patients With Motor Response Fluctuations , 1991, Clinical neuropharmacology.

[13]  P. Bédard,et al.  Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys , 1996, Brain Research.

[14]  O Rascol.  A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group , 2000 .

[15]  O. Rascol.  L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach. , 1999, Movement disorders : official journal of the Movement Disorder Society.

[16]  D. Brooks,et al.  A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. , 2000, The New England journal of medicine.

[17]  R. Pearce.  L-dopa and dyskinesias in normal monkeys. , 1999, Movement disorders : official journal of the Movement Disorder Society.

[18]  C. Gerfen,et al.  Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats , 1991, Brain Research.

[19]  R. Marconi,et al.  Pergolide monotherapy in the treatment of early PD , 1999, Neurology.

[20]  O. Rascol.  The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson’s disease , 2000, Journal of Neurology.

[21]  Y. Agid,et al.  Levodopa‐induced dyskinesias in Parkinson's disease phenomenology and pathophysiology , 1994, Movement disorders : official journal of the Movement Disorder Society.

[22]  C. Marsden,et al.  Entacapone enhances levodopa‐induced reversal of motor disability in MPTP‐treated common marmosets , 1997, Movement disorders : official journal of the Movement Disorder Society.

[23]  C. Marsden,et al.  Treatment with a selective MAO B inhibitor prevents loss of dopamine in the nucleus accumbens of MPTP-treated common marmosets , 1989, Neuropharmacology.

[24]  J G Nutt,et al.  Levodopa‐induced dyskinesia , 1990, Neurology.

[25]  H. Ruottinen,et al.  A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. , 1996, Clinical neuropharmacology.

[26]  John Seibyl,et al.  Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. , 2000, JAMA.

[27]  P. Jenner,et al.  Chronic L‐DOPA administration induces dyskinesias in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmoset (Callithrix jacchus) , 1995, Movement disorders : official journal of the Movement Disorder Society.

[28]  J. Bennett,et al.  Suppression of dyskinesias in advanced Parkinson's disease , 1993, Neurology.

[29]  P. Jenner,et al.  De novo administration of ropinirole and bromocriptine induces less dyskinesia than L‐dopa in the MPTP‐treated marmoset , 1998, Movement disorders : official journal of the Movement Disorder Society.

[30]  I. Heuser,et al.  Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease , 1990, Annals of neurology.

[31]  O. Rascol,et al.  A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[32]  R. Robertson,et al.  MPTP-Induced Parkinsonism in the Monkey: Neurochemical Pathology, Complications of Treatment and Pathophysiological Mechanisms , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[33]  I. Mitchell,et al.  Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) , 1987, Journal of the Neurological Sciences.

[34]  P. Bédard,et al.  Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. , 1991, The Journal of pharmacology and experimental therapeutics.

[35]  M. da Prada,et al.  Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats. , 1995, European journal of pharmacology.

[36]  T. Paolo,et al.  Chronic treatment withl-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding , 1986, Brain Research.

[37]  J. Nutt.  Clinical pharmacology of levodopa-induced dyskinesia. , 2000, Annals of neurology.

[38]  T. Di Paolo,et al.  Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys. , 1988, European journal of pharmacology.

[39]  J. Kulisevsky,et al.  A Six‐month Study of Pergolide and Levodopa in De Novo Parkinson's Disease Patients , 1998, Clinical neuropharmacology.

[40]  T. Engber,et al.  Responses of substantia nigra pars reticulata neurons to GABA and SKF 38393 in 6-hydroxydopamine-lesioned rats are differentially affected by continuous and intermittent levodopa administration , 1990, Brain Research.

[41]  D. D. Di Monte,et al.  Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model , 2000, Movement disorders : official journal of the Movement Disorder Society.

[42]  M. Piercey,et al.  Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. , 1995, The Journal of pharmacology and experimental therapeutics.

[43]  C. Marsden,et al.  Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP-treated common marmosets , 2005, Psychopharmacology.

[44]  J A Obeso,et al.  Preventing levodopa-induced dyskinesias. , 2000, Annals of neurology.

[45]  R. Wurtman,et al.  Effects of Catechol‐O‐Methyltransferase Inhibitors and L‐3,4‐Dihydroxyphenylalanine With or Without Carbidopa on Extracellular Dopamine in Rat Striatum , 1993, Journal of neurochemistry.